The Minimal Residual Disease Testing market involves the monitoring of response to anti-cancer therapies by detecting and quantifying residual malignant disease below the threshold of conventional detection methods. It enables assessment of treatment response through detection of cancer cells at frequencies as low as 1 in 104-105 nucleated cells, thereby allowing for treatment strategy...
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian